Search research articles
Contact Us
Filters
Showing results (361-370 of 372) with videos related to
Page
of 38
Sort By:
Bioengineered
|
August 11, 2020
Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?
Xun Lai, Yun Yan Sun, Lung Ji Chang, et al.
Journal of Infection and Public Health
|
March 14, 2025
Early differential diagnosis models of Talaromycosis and Tuberculosis in HIV-negative hosts using clinical data and machine learning
Ye Qiu, Zheng-Tu Li, Shi-Xiong Yang, et al.
Neurochemistry International
|
August 13, 2021
Voltage-dependent potassium channel Kv4.2 alleviates the ischemic stroke impairments through activating neurogenesis
Fuyao Xiao, Xiaojie Zhang, Pinfei Ni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
March 13, 2026
Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study
Wang Liao, Qun Yu, Bin Chen, et al.
Scientific Reports
|
June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)
Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Hepatology (Baltimore, Md.)
|
February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer
|
June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study
Da-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Hepatology (Baltimore, Md.)
|
June 25, 2025
Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer
|
January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)
Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
Communications Medicine
|
March 13, 2026
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)
Da-Long Yang, Chuang Qin, Ning Peng, et al.
Page
of 38
Search research articles
Search
Showing results (361-370 of 372) with videos related to
Sort By:
Page
of 38
Bioengineered
|
August 11, 2020
Could cytokine release syndrome induce acute myelofibrosis in CD19 chimeric antigen receptor T cells therapy?
Xun Lai, Yun Yan Sun, Lung Ji Chang, et al.
Journal of Infection and Public Health
|
March 14, 2025
Early differential diagnosis models of Talaromycosis and Tuberculosis in HIV-negative hosts using clinical data and machine learning
Ye Qiu, Zheng-Tu Li, Shi-Xiong Yang, et al.
Neurochemistry International
|
August 13, 2021
Voltage-dependent potassium channel Kv4.2 alleviates the ischemic stroke impairments through activating neurogenesis
Fuyao Xiao, Xiaojie Zhang, Pinfei Ni, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
March 13, 2026
Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study
Wang Liao, Qun Yu, Bin Chen, et al.
Scientific Reports
|
June 2, 2026
Progression-free survival as a potential surrogate endpoint for overall survival after conversion therapy for unresectable hepatocellular carcinoma (GUIDANCE008)
Jin-Wei Wu, Da-Long Yang, Shu-Chang Chen, et al.
Hepatology (Baltimore, Md.)
|
February 5, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer
|
June 11, 2025
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study
Da-Long Yang, Ning Peng, Jun-Liang Nong, et al.
Hepatology (Baltimore, Md.)
|
June 25, 2025
Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
Da-Long Yang, Lin Ye, Fan-Jian Zeng, et al.
Liver Cancer
|
January 19, 2026
Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma (GUIDANCE006)
Liang Ma, Da-Long Yang, Teng-Meng Zhong, et al.
Communications Medicine
|
March 13, 2026
Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)
Da-Long Yang, Chuang Qin, Ning Peng, et al.
Page
of 38